ストックスクリーナーアプリを入手
62.69
0.71%
0.44
アフターアワーズ：
62.69
前日終値:
$62.25
開ける：
$62.27
24時間の取引高:
237.65K
Relative Volume:
1.45
時価総額：
$693.33M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+10.58%
1か月 パフォーマンス:
+15.77%
6か月 パフォーマンス:
+123.97%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$62.02
$65.57
1週間の範囲:
$56.55
$65.57
52週間の値動き範囲:
$11.17
$65.57
Palvella Therapeutics Inc Stock (PVLA) Company Profile
PVLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
62.69 | 688.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-06 | 開始されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-04-09 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-26 | 開始されました | Stifel | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-05 | 開始されました | TD Cowen | Buy |
| 2024-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 開始されました | Jefferies | Buy |
| 2018-01-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-30 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-05 | 再開されました | ROTH Capital | Buy |
| 2015-08-12 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-07-27 | 開始されました | Oppenheimer | Outperform |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
すべてを表示
Palvella Therapeutics Inc (PVLA) 最新ニュース
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthSwing Trade & Technical Pattern Based Buy Signals - newser.com
Tick level data insight on Palvella Therapeutics Inc. volatilityEarnings Beat & Weekly High Potential Stock Alerts - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stockJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat
Published on: 2025-09-29 15:57:39 - newser.com
Can Palvella Therapeutics Inc. (PI6) stock attract ESG investmentsProfit Target & AI Enhanced Trading Alerts - newser.com
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsJuly 2025 Earnings & High Win Rate Trade Alerts - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Trade Analysis Report & Risk Managed Trade Strategies - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportJuly 2025 Review & Entry Point Confirmation Alerts - newser.com
Published on: 2025-09-29 09:58:44 - newser.com
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas - MyChesCo
Published on: 2025-09-29 07:36:24 - newser.com
Equities Analysts Offer Predictions for PVLA FY2028 Earnings - Defense World
Published on: 2025-09-28 21:37:00 - newser.com
Palvella Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Budget Friendly Portfolio - earlytimes.in
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MyChesCo
What analysts say about Palvella Therapeutics Inc stockHealthcare Stock Analysis & Minimal Investment Capital - earlytimes.in
Palvella Expands QTORIN Gel Program for Rare Disease - MSN
Best data tools to analyze Palvella Therapeutics Inc. stockPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com
Published on: 2025-09-27 05:34:37 - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Analyst Downgrade & Long Hold Capital Preservation Tips - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital - MarketBeat
Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics stock price target raised to $70 at Jones Trading - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments By Investing.com - Investing.com South Africa
Stifel Maintains 'Buy' Rating and Raises Price Target for PVLA t - GuruFocus
Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00 - MarketBeat
Palvella Therapeutics stock price target raised to $80 by Stifel on new skin treatment - Investing.com Canada
Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer - Investing.com UK
Palvella to develop therapy for rare skin condition with no approved treatments - Investing.com Canada
Palvella Therapeutics Announces Expansion of QTORIN™ - GlobeNewswire
No FDA Treatment Exists: Palvella Targets 50,000 Patients with Rare Bleeding Skin Disease in New Trial - Stock Titan
Palvella Therapeutics Inc (PVLA) 財務データ
Palvella Therapeutics Inc (PVLA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):